| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia | 27 | 2023 | 751 | 8.230 |
Why?
|
| Community-Acquired Infections | 34 | 2023 | 285 | 7.830 |
Why?
|
| Pneumonia, Pneumococcal | 24 | 2019 | 74 | 6.970 |
Why?
|
| Streptococcus pneumoniae | 26 | 2022 | 330 | 5.790 |
Why?
|
| Pneumococcal Vaccines | 19 | 2016 | 161 | 5.060 |
Why?
|
| Pneumonia, Bacterial | 11 | 2022 | 130 | 4.790 |
Why?
|
| Anti-Bacterial Agents | 48 | 2023 | 2992 | 4.200 |
Why?
|
| Pneumococcal Infections | 16 | 2016 | 241 | 4.170 |
Why?
|
| Enterocolitis, Pseudomembranous | 13 | 2016 | 111 | 3.270 |
Why?
|
| Sputum | 7 | 2023 | 141 | 2.120 |
Why?
|
| Bacteremia | 14 | 2021 | 689 | 2.080 |
Why?
|
| Staphylococcal Infections | 13 | 2017 | 672 | 1.840 |
Why?
|
| Bacteriology | 2 | 2023 | 4 | 1.800 |
Why?
|
| Osteomyelitis | 5 | 2022 | 236 | 1.760 |
Why?
|
| Staphylococcus aureus | 13 | 2017 | 548 | 1.760 |
Why?
|
| Antibodies, Bacterial | 7 | 2017 | 380 | 1.620 |
Why?
|
| Myocardial Infarction | 10 | 2022 | 1374 | 1.460 |
Why?
|
| Vaccines, Conjugate | 5 | 2016 | 76 | 1.370 |
Why?
|
| Polysaccharides, Bacterial | 3 | 2023 | 67 | 1.350 |
Why?
|
| Clostridium Infections | 5 | 2012 | 252 | 1.300 |
Why?
|
| Bacterial Infections | 5 | 2018 | 479 | 1.230 |
Why?
|
| Humans | 159 | 2023 | 261506 | 1.140 |
Why?
|
| Haemophilus Infections | 5 | 2019 | 103 | 1.130 |
Why?
|
| Methicillin Resistance | 7 | 2008 | 147 | 1.020 |
Why?
|
| Anti-Infective Agents | 4 | 2015 | 446 | 1.000 |
Why?
|
| Macrolides | 5 | 2019 | 62 | 0.950 |
Why?
|
| Neurosyphilis | 2 | 2016 | 9 | 0.920 |
Why?
|
| Communicable Diseases | 2 | 2022 | 193 | 0.910 |
Why?
|
| Syphilis | 4 | 2019 | 61 | 0.910 |
Why?
|
| Metronidazole | 5 | 2007 | 149 | 0.900 |
Why?
|
| Thiazoles | 4 | 2009 | 726 | 0.900 |
Why?
|
| Endocarditis | 3 | 2020 | 125 | 0.890 |
Why?
|
| Salmonella Infections | 2 | 2013 | 40 | 0.880 |
Why?
|
| Nucleic Acids | 1 | 2023 | 43 | 0.880 |
Why?
|
| Meningococcal Vaccines | 3 | 2008 | 31 | 0.870 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2017 | 1021 | 0.840 |
Why?
|
| Severity of Illness Index | 13 | 2019 | 4320 | 0.800 |
Why?
|
| Pneumonia, Viral | 2 | 2022 | 715 | 0.800 |
Why?
|
| Bacterial Toxins | 4 | 2007 | 228 | 0.780 |
Why?
|
| Hospitalization | 11 | 2022 | 2083 | 0.780 |
Why?
|
| Immunoglobulin G | 6 | 2017 | 1021 | 0.770 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 4 | 2015 | 28 | 0.770 |
Why?
|
| Laboratories | 1 | 2021 | 145 | 0.750 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 86 | 0.730 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 149 | 0.720 |
Why?
|
| Oral Ulcer | 1 | 2019 | 15 | 0.710 |
Why?
|
| Coinfection | 1 | 2021 | 189 | 0.700 |
Why?
|
| Cross Infection | 9 | 2012 | 544 | 0.700 |
Why?
|
| Protective Clothing | 1 | 2019 | 10 | 0.700 |
Why?
|
| Health Occupations | 1 | 2019 | 18 | 0.690 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2014 | 994 | 0.680 |
Why?
|
| Bacteria | 4 | 2023 | 611 | 0.670 |
Why?
|
| Rhodococcus equi | 1 | 2018 | 8 | 0.660 |
Why?
|
| Actinomycetales Infections | 1 | 2018 | 15 | 0.650 |
Why?
|
| Male | 71 | 2019 | 123000 | 0.640 |
Why?
|
| Gram-Positive Bacteria | 2 | 2011 | 66 | 0.630 |
Why?
|
| Respiratory Tract Infections | 3 | 2018 | 437 | 0.630 |
Why?
|
| Vancomycin | 7 | 2012 | 273 | 0.620 |
Why?
|
| Gram-Negative Bacteria | 2 | 2011 | 100 | 0.620 |
Why?
|
| Immunization Schedule | 3 | 2016 | 117 | 0.620 |
Why?
|
| Rickettsia typhi | 1 | 2017 | 12 | 0.610 |
Why?
|
| Documentation | 1 | 2019 | 207 | 0.610 |
Why?
|
| Typhus, Endemic Flea-Borne | 1 | 2017 | 19 | 0.600 |
Why?
|
| Haemophilus influenzae | 2 | 2009 | 144 | 0.600 |
Why?
|
| Drug Utilization | 2 | 2016 | 179 | 0.590 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.580 |
Why?
|
| Virus Diseases | 3 | 2013 | 398 | 0.570 |
Why?
|
| Enterotoxins | 2 | 2007 | 112 | 0.570 |
Why?
|
| Acute Coronary Syndrome | 2 | 2010 | 259 | 0.560 |
Why?
|
| Aged | 45 | 2019 | 70117 | 0.560 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 3203 | 0.560 |
Why?
|
| Abscess | 3 | 2008 | 177 | 0.550 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2016 | 46 | 0.550 |
Why?
|
| Spores, Bacterial | 1 | 2016 | 49 | 0.550 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2016 | 68 | 0.550 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2013 | 849 | 0.540 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 4 | 2014 | 308 | 0.540 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2018 | 238 | 0.530 |
Why?
|
| Secondary Prevention | 2 | 2016 | 329 | 0.530 |
Why?
|
| Aerococcus | 1 | 2014 | 1 | 0.510 |
Why?
|
| Lipoproteins | 1 | 2016 | 252 | 0.510 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2014 | 157 | 0.510 |
Why?
|
| Bacteriuria | 3 | 2013 | 77 | 0.510 |
Why?
|
| Leukocytosis | 3 | 2006 | 112 | 0.510 |
Why?
|
| Sinusitis | 2 | 2007 | 131 | 0.510 |
Why?
|
| Middle Aged | 51 | 2018 | 86204 | 0.500 |
Why?
|
| Immunization, Secondary | 2 | 2016 | 110 | 0.490 |
Why?
|
| Fever | 1 | 2017 | 497 | 0.490 |
Why?
|
| Cognition | 1 | 2020 | 968 | 0.490 |
Why?
|
| Developed Countries | 1 | 2014 | 42 | 0.480 |
Why?
|
| Influenza, Human | 1 | 2021 | 925 | 0.470 |
Why?
|
| Ceftriaxone | 4 | 2013 | 67 | 0.470 |
Why?
|
| Female | 54 | 2019 | 141928 | 0.460 |
Why?
|
| Salmonella enteritidis | 1 | 2013 | 7 | 0.460 |
Why?
|
| Adult | 39 | 2023 | 77950 | 0.460 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 1399 | 0.460 |
Why?
|
| Urinary Tract Infections | 3 | 2012 | 321 | 0.450 |
Why?
|
| Acute Disease | 7 | 2019 | 2422 | 0.450 |
Why?
|
| Aneurysm, Infected | 1 | 2013 | 32 | 0.450 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2018 | 163 | 0.440 |
Why?
|
| Bacterial Typing Techniques | 2 | 2010 | 139 | 0.440 |
Why?
|
| Mountaineering | 1 | 2012 | 3 | 0.430 |
Why?
|
| Vasculitis | 1 | 2012 | 61 | 0.430 |
Why?
|
| Nail Diseases | 1 | 2012 | 40 | 0.420 |
Why?
|
| Serotyping | 5 | 2016 | 166 | 0.410 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2012 | 72 | 0.410 |
Why?
|
| Necrosis | 2 | 2011 | 580 | 0.410 |
Why?
|
| Streptococcus | 2 | 2009 | 68 | 0.410 |
Why?
|
| Viruses | 1 | 2013 | 159 | 0.400 |
Why?
|
| Hepatitis C | 1 | 2017 | 524 | 0.400 |
Why?
|
| Vaccination | 7 | 2016 | 1123 | 0.400 |
Why?
|
| Azithromycin | 1 | 2011 | 78 | 0.400 |
Why?
|
| Bacterial Proteins | 3 | 2012 | 1029 | 0.400 |
Why?
|
| Aneurysm, False | 1 | 2013 | 153 | 0.390 |
Why?
|
| Electronic Health Records | 1 | 2019 | 929 | 0.390 |
Why?
|
| Physicians | 1 | 2019 | 882 | 0.380 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 203 | 0.380 |
Why?
|
| Staphylococcus | 1 | 2010 | 86 | 0.370 |
Why?
|
| Thinness | 1 | 2010 | 82 | 0.370 |
Why?
|
| Catheter-Related Infections | 3 | 2012 | 270 | 0.360 |
Why?
|
| Syphilis, Cutaneous | 2 | 2011 | 8 | 0.360 |
Why?
|
| Treatment Outcome | 14 | 2016 | 32848 | 0.350 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 332 | 0.350 |
Why?
|
| Incidence | 11 | 2017 | 5673 | 0.350 |
Why?
|
| Suction | 2 | 2006 | 104 | 0.350 |
Why?
|
| Immunocompromised Host | 3 | 2020 | 698 | 0.350 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 918 | 0.340 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2008 | 10 | 0.340 |
Why?
|
| Disease Progression | 2 | 2019 | 6682 | 0.340 |
Why?
|
| Endocarditis, Bacterial | 3 | 2007 | 128 | 0.340 |
Why?
|
| Hospitals, Veterans | 3 | 2007 | 397 | 0.330 |
Why?
|
| Aged, 80 and over | 22 | 2018 | 29902 | 0.330 |
Why?
|
| Retrospective Studies | 22 | 2022 | 37905 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 2403 | 0.330 |
Why?
|
| Intensive Care Units | 5 | 2016 | 717 | 0.330 |
Why?
|
| Risk Factors | 15 | 2019 | 17523 | 0.320 |
Why?
|
| Nitro Compounds | 4 | 2009 | 23 | 0.310 |
Why?
|
| Antiparasitic Agents | 1 | 2007 | 39 | 0.310 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 461 | 0.310 |
Why?
|
| Colitis | 2 | 2009 | 340 | 0.310 |
Why?
|
| Bone Diseases, Infectious | 1 | 2007 | 12 | 0.310 |
Why?
|
| Indium Radioisotopes | 1 | 2007 | 65 | 0.300 |
Why?
|
| Soft Tissue Infections | 2 | 2018 | 102 | 0.300 |
Why?
|
| Cavernous Sinus Thrombosis | 1 | 2007 | 7 | 0.300 |
Why?
|
| Hemorrhage | 1 | 2012 | 712 | 0.300 |
Why?
|
| Immunologic Factors | 1 | 2011 | 649 | 0.300 |
Why?
|
| Calcitonin | 2 | 2020 | 186 | 0.300 |
Why?
|
| Comorbidity | 7 | 2016 | 2352 | 0.300 |
Why?
|
| Disease Outbreaks | 2 | 2009 | 415 | 0.300 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 622 | 0.300 |
Why?
|
| Lung Abscess | 1 | 2006 | 13 | 0.300 |
Why?
|
| Overweight | 1 | 2010 | 484 | 0.290 |
Why?
|
| Bacteriological Techniques | 2 | 2005 | 121 | 0.290 |
Why?
|
| Hyperglycemia | 1 | 2009 | 333 | 0.290 |
Why?
|
| Protein Precursors | 2 | 2020 | 240 | 0.290 |
Why?
|
| Superantigens | 1 | 2006 | 29 | 0.280 |
Why?
|
| Immunity, Herd | 1 | 2006 | 20 | 0.280 |
Why?
|
| Feces | 2 | 2007 | 770 | 0.280 |
Why?
|
| Tomography, Emission-Computed | 1 | 2007 | 310 | 0.280 |
Why?
|
| Pyelonephritis | 1 | 2006 | 39 | 0.270 |
Why?
|
| Peritonitis | 1 | 2006 | 89 | 0.270 |
Why?
|
| Heptanoic Acids | 1 | 2006 | 96 | 0.270 |
Why?
|
| Pulmonary Emphysema | 1 | 2006 | 145 | 0.260 |
Why?
|
| Conflict of Interest | 1 | 2006 | 98 | 0.260 |
Why?
|
| Leukocytes | 1 | 2007 | 422 | 0.260 |
Why?
|
| Emphysema | 1 | 2006 | 87 | 0.260 |
Why?
|
| Proton Pump Inhibitors | 1 | 2007 | 249 | 0.260 |
Why?
|
| Diabetes Complications | 3 | 2013 | 305 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2013 | 7551 | 0.260 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 1165 | 0.260 |
Why?
|
| Polysaccharides | 2 | 2018 | 197 | 0.250 |
Why?
|
| Texas | 6 | 2017 | 6311 | 0.250 |
Why?
|
| Prospective Studies | 12 | 2016 | 12873 | 0.240 |
Why?
|
| Treponema pallidum | 3 | 2019 | 29 | 0.240 |
Why?
|
| Splenectomy | 1 | 2005 | 158 | 0.240 |
Why?
|
| Time Factors | 8 | 2014 | 12926 | 0.240 |
Why?
|
| Amoxicillin | 1 | 2005 | 106 | 0.240 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 739 | 0.240 |
Why?
|
| United States | 10 | 2022 | 15433 | 0.240 |
Why?
|
| Microscopy | 3 | 2021 | 182 | 0.230 |
Why?
|
| Empyema, Pleural | 1 | 2003 | 48 | 0.230 |
Why?
|
| Anticholesteremic Agents | 1 | 2006 | 256 | 0.220 |
Why?
|
| Sensitivity and Specificity | 7 | 2015 | 4971 | 0.220 |
Why?
|
| Cause of Death | 2 | 2018 | 752 | 0.220 |
Why?
|
| Urine | 2 | 2013 | 143 | 0.220 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2022 | 13 | 0.210 |
Why?
|
| Doxycycline | 1 | 2023 | 178 | 0.210 |
Why?
|
| Virulence | 4 | 2012 | 323 | 0.210 |
Why?
|
| Critical Care | 1 | 2008 | 770 | 0.210 |
Why?
|
| Administration, Intravenous | 2 | 2020 | 249 | 0.210 |
Why?
|
| Pyrroles | 1 | 2006 | 576 | 0.210 |
Why?
|
| Risk Assessment | 6 | 2018 | 6869 | 0.200 |
Why?
|
| Hydroxyurea | 1 | 2002 | 204 | 0.200 |
Why?
|
| Blood | 2 | 2013 | 156 | 0.200 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2003 | 317 | 0.200 |
Why?
|
| Recurrence | 6 | 2007 | 4758 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 2594 | 0.190 |
Why?
|
| Allergy and Immunology | 1 | 2021 | 29 | 0.190 |
Why?
|
| History, 19th Century | 1 | 2021 | 154 | 0.190 |
Why?
|
| Phenazines | 2 | 2014 | 13 | 0.190 |
Why?
|
| Spinal Diseases | 2 | 2014 | 125 | 0.190 |
Why?
|
| Gentian Violet | 2 | 2014 | 20 | 0.190 |
Why?
|
| Shock, Septic | 1 | 2022 | 181 | 0.180 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2016 | 171 | 0.180 |
Why?
|
| Palate, Hard | 1 | 2019 | 12 | 0.180 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 589 | 0.180 |
Why?
|
| Fraud | 1 | 2019 | 18 | 0.180 |
Why?
|
| Animals | 10 | 2022 | 59536 | 0.180 |
Why?
|
| Patient Care Management | 1 | 2020 | 94 | 0.180 |
Why?
|
| Viremia | 1 | 2020 | 177 | 0.180 |
Why?
|
| Laundering | 1 | 2019 | 1 | 0.180 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2019 | 16 | 0.170 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2020 | 163 | 0.170 |
Why?
|
| Tertiary Care Centers | 3 | 2018 | 403 | 0.170 |
Why?
|
| Anemia | 1 | 2004 | 689 | 0.170 |
Why?
|
| Prognosis | 7 | 2020 | 21713 | 0.170 |
Why?
|
| Immunologic Memory | 1 | 2021 | 374 | 0.170 |
Why?
|
| Troponin | 1 | 2019 | 92 | 0.160 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2006 | 418 | 0.160 |
Why?
|
| Cardiovascular Diseases | 2 | 2013 | 2195 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 3719 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2021 | 574 | 0.160 |
Why?
|
| Age Factors | 5 | 2018 | 5377 | 0.160 |
Why?
|
| Obesity | 1 | 2010 | 2884 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2010 | 6100 | 0.160 |
Why?
|
| Colony Count, Microbial | 3 | 2012 | 149 | 0.150 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 3472 | 0.150 |
Why?
|
| HIV Infections | 3 | 2011 | 2134 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2011 | 544 | 0.150 |
Why?
|
| Physical Examination | 1 | 2019 | 299 | 0.150 |
Why?
|
| Intestinal Perforation | 1 | 2018 | 102 | 0.150 |
Why?
|
| Zoonoses | 1 | 2017 | 55 | 0.150 |
Why?
|
| Logistic Models | 5 | 2015 | 3441 | 0.150 |
Why?
|
| Young Adult | 6 | 2017 | 21445 | 0.150 |
Why?
|
| Klebsiella Infections | 1 | 1997 | 64 | 0.150 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 509 | 0.150 |
Why?
|
| Exanthema | 1 | 2019 | 211 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 6207 | 0.150 |
Why?
|
| Thigh | 1 | 2018 | 172 | 0.150 |
Why?
|
| Serogroup | 1 | 2016 | 50 | 0.150 |
Why?
|
| Klebsiella pneumoniae | 1 | 1997 | 98 | 0.150 |
Why?
|
| Symptom Flare Up | 1 | 2016 | 22 | 0.140 |
Why?
|
| Survival Rate | 4 | 2018 | 12221 | 0.140 |
Why?
|
| Confidence Intervals | 2 | 2009 | 756 | 0.140 |
Why?
|
| Legionella | 1 | 2016 | 18 | 0.140 |
Why?
|
| Protective Factors | 1 | 2016 | 106 | 0.140 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 4988 | 0.140 |
Why?
|
| Pneumocystis carinii | 1 | 2016 | 20 | 0.140 |
Why?
|
| Immunoglobulin M | 1 | 2017 | 347 | 0.140 |
Why?
|
| Dissent and Disputes | 1 | 2016 | 41 | 0.140 |
Why?
|
| Antimicrobial Stewardship | 1 | 2017 | 84 | 0.140 |
Why?
|
| Adolescent | 7 | 2017 | 31252 | 0.140 |
Why?
|
| Ethics, Medical | 1 | 2019 | 442 | 0.140 |
Why?
|
| Abdominal Wall | 1 | 2018 | 184 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 14889 | 0.130 |
Why?
|
| DNA, Bacterial | 1 | 1997 | 558 | 0.130 |
Why?
|
| Medical Records | 2 | 2007 | 415 | 0.130 |
Why?
|
| Heart Failure | 3 | 2018 | 2516 | 0.130 |
Why?
|
| Advisory Committees | 1 | 2016 | 203 | 0.130 |
Why?
|
| Haemophilus influenzae type b | 1 | 2014 | 8 | 0.120 |
Why?
|
| Haemophilus Vaccines | 1 | 2014 | 40 | 0.120 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 2315 | 0.120 |
Why?
|
| Carrier State | 1 | 2014 | 90 | 0.120 |
Why?
|
| Radiography, Thoracic | 2 | 2019 | 462 | 0.120 |
Why?
|
| Epidural Abscess | 1 | 2014 | 12 | 0.120 |
Why?
|
| Lung | 2 | 2018 | 3151 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2013 | 1819 | 0.120 |
Why?
|
| Biomarkers | 2 | 2020 | 5047 | 0.120 |
Why?
|
| Publishing | 1 | 2016 | 220 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 4892 | 0.120 |
Why?
|
| Nasal Cavity | 1 | 2014 | 149 | 0.120 |
Why?
|
| Scedosporium | 1 | 2013 | 23 | 0.110 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2013 | 19 | 0.110 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 635 | 0.110 |
Why?
|
| Microbiological Techniques | 1 | 2012 | 40 | 0.110 |
Why?
|
| Urinary Catheterization | 2 | 2013 | 117 | 0.110 |
Why?
|
| Treatment Failure | 2 | 2007 | 1391 | 0.110 |
Why?
|
| Pyomyositis | 1 | 2012 | 9 | 0.110 |
Why?
|
| Syndrome | 1 | 2016 | 1351 | 0.110 |
Why?
|
| Disease Management | 1 | 2018 | 1052 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 120 | 0.110 |
Why?
|
| Dialysis | 1 | 2012 | 23 | 0.110 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2003 | 297 | 0.110 |
Why?
|
| Daptomycin | 1 | 2012 | 39 | 0.110 |
Why?
|
| Myocardium | 1 | 2019 | 1313 | 0.110 |
Why?
|
| Seoul virus | 1 | 2011 | 2 | 0.110 |
Why?
|
| Hantavirus Pulmonary Syndrome | 1 | 2011 | 3 | 0.110 |
Why?
|
| Altitude | 1 | 2012 | 39 | 0.100 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 231 | 0.100 |
Why?
|
| Mortality | 2 | 2012 | 343 | 0.100 |
Why?
|
| Genome, Bacterial | 1 | 2012 | 200 | 0.100 |
Why?
|
| Cephalosporins | 1 | 2012 | 148 | 0.100 |
Why?
|
| Aminoglycosides | 1 | 2012 | 220 | 0.100 |
Why?
|
| Catheters | 1 | 2012 | 126 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1303 | 0.100 |
Why?
|
| Respiratory Paralysis | 1 | 2010 | 8 | 0.100 |
Why?
|
| Skin Ulcer | 1 | 2011 | 77 | 0.100 |
Why?
|
| Pelvis | 1 | 2013 | 362 | 0.100 |
Why?
|
| Tertiary Prevention | 1 | 2010 | 3 | 0.100 |
Why?
|
| Methicillin | 1 | 2010 | 49 | 0.100 |
Why?
|
| ROC Curve | 1 | 2014 | 1183 | 0.100 |
Why?
|
| Urea | 1 | 2012 | 290 | 0.090 |
Why?
|
| Blood Culture | 2 | 2021 | 32 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2013 | 495 | 0.090 |
Why?
|
| Thiazolidinediones | 1 | 2011 | 148 | 0.090 |
Why?
|
| Age Distribution | 2 | 2013 | 698 | 0.090 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 295 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 4298 | 0.090 |
Why?
|
| Culture Media | 1 | 2010 | 319 | 0.090 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 268 | 0.090 |
Why?
|
| Creatinine | 1 | 2012 | 531 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2011 | 298 | 0.090 |
Why?
|
| Phagocytosis | 2 | 2008 | 260 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 7222 | 0.090 |
Why?
|
| Hemolysis | 1 | 2009 | 127 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2020 | 1544 | 0.090 |
Why?
|
| Antidiarrheals | 1 | 2009 | 37 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4314 | 0.080 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 1320 | 0.080 |
Why?
|
| Placebos | 1 | 2010 | 437 | 0.080 |
Why?
|
| beta-Lactamases | 1 | 2011 | 179 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2016 | 2316 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2016 | 2022 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 473 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 2307 | 0.080 |
Why?
|
| Aspirin | 1 | 2011 | 455 | 0.080 |
Why?
|
| Dyspnea | 1 | 2010 | 416 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2014 | 1171 | 0.080 |
Why?
|
| Child | 4 | 2017 | 29154 | 0.080 |
Why?
|
| Infant | 3 | 2014 | 13310 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 732 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2013 | 691 | 0.070 |
Why?
|
| Fever of Unknown Origin | 1 | 2007 | 63 | 0.070 |
Why?
|
| Clindamycin | 1 | 2006 | 50 | 0.070 |
Why?
|
| Survivors | 1 | 2013 | 1031 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 945 | 0.070 |
Why?
|
| Mice | 4 | 2017 | 34495 | 0.070 |
Why?
|
| Parasitic Diseases | 1 | 2007 | 65 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2012 | 684 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 408 | 0.070 |
Why?
|
| Blood Bactericidal Activity | 1 | 2006 | 18 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2014 | 16273 | 0.070 |
Why?
|
| Consensus | 2 | 2020 | 978 | 0.070 |
Why?
|
| Gastroenteritis | 1 | 2009 | 300 | 0.070 |
Why?
|
| Caliciviridae Infections | 1 | 2009 | 279 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 220 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2009 | 4744 | 0.070 |
Why?
|
| Norovirus | 1 | 2009 | 287 | 0.070 |
Why?
|
| Vancomycin Resistance | 1 | 2005 | 54 | 0.070 |
Why?
|
| Coronary Disease | 1 | 2010 | 764 | 0.070 |
Why?
|
| Probability | 1 | 2007 | 866 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2007 | 362 | 0.070 |
Why?
|
| Rabbits | 2 | 2006 | 957 | 0.060 |
Why?
|
| Foodborne Diseases | 1 | 2004 | 11 | 0.060 |
Why?
|
| Diarrhea | 1 | 2009 | 686 | 0.060 |
Why?
|
| Protozoan Infections | 1 | 2004 | 16 | 0.060 |
Why?
|
| Outpatients | 2 | 2012 | 462 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 1011 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1945 | 0.060 |
Why?
|
| Tachycardia, Ventricular | 1 | 2007 | 239 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2006 | 519 | 0.060 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2005 | 158 | 0.060 |
Why?
|
| Catheterization | 1 | 2006 | 410 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 2006 | 241 | 0.060 |
Why?
|
| Neisseria meningitidis | 1 | 2003 | 23 | 0.060 |
Why?
|
| Nursing Homes | 2 | 2016 | 99 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 598 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2009 | 2588 | 0.060 |
Why?
|
| Rhinovirus | 1 | 2003 | 94 | 0.060 |
Why?
|
| Orthomyxoviridae | 1 | 2003 | 94 | 0.060 |
Why?
|
| Mycobacterium Infections | 1 | 2003 | 49 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2010 | 2203 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2004 | 429 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 690 | 0.050 |
Why?
|
| Probiotics | 1 | 2005 | 228 | 0.050 |
Why?
|
| Survival Analysis | 4 | 2018 | 9180 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2022 | 1274 | 0.050 |
Why?
|
| Mycobacterium bovis | 1 | 2003 | 67 | 0.050 |
Why?
|
| Algorithms | 1 | 2014 | 3890 | 0.050 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2002 | 28 | 0.050 |
Why?
|
| Streptococcus pyogenes | 1 | 2003 | 119 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2006 | 1038 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2002 | 218 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8223 | 0.050 |
Why?
|
| Antigens, Bacterial | 2 | 2019 | 354 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 10001 | 0.050 |
Why?
|
| Cell Survival | 1 | 2007 | 3045 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2007 | 1682 | 0.050 |
Why?
|
| Moraxellaceae Infections | 1 | 2019 | 4 | 0.050 |
Why?
|
| Chlamydophila Infections | 1 | 2019 | 4 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 182 | 0.050 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2019 | 13 | 0.040 |
Why?
|
| Culture Techniques | 1 | 2019 | 132 | 0.040 |
Why?
|
| BCG Vaccine | 1 | 2003 | 399 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 6009 | 0.040 |
Why?
|
| Legionellosis | 1 | 2019 | 17 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2002 | 829 | 0.040 |
Why?
|
| Remission Induction | 1 | 2006 | 3569 | 0.040 |
Why?
|
| beta-Lactams | 1 | 2019 | 53 | 0.040 |
Why?
|
| Gangrene | 1 | 2018 | 28 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2001 | 280 | 0.040 |
Why?
|
| Foot Ulcer | 1 | 2018 | 21 | 0.040 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2003 | 426 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2002 | 492 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 8865 | 0.040 |
Why?
|
| Mannose | 1 | 1997 | 40 | 0.040 |
Why?
|
| Debridement | 1 | 2018 | 123 | 0.040 |
Why?
|
| Binding Sites | 1 | 2002 | 2171 | 0.040 |
Why?
|
| Fimbriae, Bacterial | 1 | 1997 | 66 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2003 | 1459 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 661 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 1997 | 91 | 0.040 |
Why?
|
| DNA Fingerprinting | 1 | 1997 | 167 | 0.040 |
Why?
|
| Neutrophils | 1 | 2001 | 835 | 0.040 |
Why?
|
| Hospitals | 2 | 2012 | 485 | 0.040 |
Why?
|
| Bacterial Adhesion | 1 | 1997 | 147 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 2390 | 0.030 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2006 | 128 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2019 | 554 | 0.030 |
Why?
|
| Neoplasms | 1 | 2021 | 15193 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2014 | 87 | 0.030 |
Why?
|
| Spinal Cord Injuries | 1 | 1997 | 374 | 0.030 |
Why?
|
| Immunotherapy | 2 | 2008 | 3341 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2018 | 9244 | 0.030 |
Why?
|
| Asymptomatic Infections | 1 | 2013 | 34 | 0.030 |
Why?
|
| Prevalence | 2 | 2012 | 3260 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 2139 | 0.030 |
Why?
|
| Africa, Western | 1 | 2012 | 16 | 0.030 |
Why?
|
| Prophages | 1 | 2012 | 6 | 0.030 |
Why?
|
| Psychosurgery | 1 | 2013 | 28 | 0.030 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2012 | 14 | 0.030 |
Why?
|
| Streptococcal Vaccines | 1 | 2012 | 17 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2012 | 46 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2013 | 185 | 0.030 |
Why?
|
| Nitrites | 1 | 2012 | 61 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 429 | 0.030 |
Why?
|
| Yeasts | 1 | 2012 | 74 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 527 | 0.030 |
Why?
|
| Chromosomes, Bacterial | 1 | 2012 | 62 | 0.030 |
Why?
|
| Brain Abscess | 1 | 2013 | 60 | 0.030 |
Why?
|
| Voriconazole | 1 | 2013 | 108 | 0.030 |
Why?
|
| Genes, Bacterial | 1 | 2012 | 236 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2013 | 289 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 482 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2012 | 469 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2013 | 145 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2003 | 980 | 0.020 |
Why?
|
| Virulence Factors | 1 | 2012 | 213 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2011 | 254 | 0.020 |
Why?
|
| Forecasting | 1 | 2014 | 694 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2003 | 1323 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 543 | 0.020 |
Why?
|
| Prosthesis-Related Infections | 1 | 2012 | 232 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2005 | 5542 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 435 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1997 | 5637 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2009 | 209 | 0.020 |
Why?
|
| Triazoles | 1 | 2013 | 617 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 1225 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 1900 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2013 | 834 | 0.020 |
Why?
|
| Leukocidins | 1 | 2006 | 46 | 0.020 |
Why?
|
| Exotoxins | 1 | 2006 | 77 | 0.020 |
Why?
|
| Inpatients | 1 | 2012 | 678 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 383 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 838 | 0.020 |
Why?
|
| Gentamicins | 1 | 2004 | 90 | 0.020 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2003 | 12 | 0.020 |
Why?
|
| Legionnaires' Disease | 1 | 2003 | 13 | 0.010 |
Why?
|
| Cefotaxime | 1 | 2003 | 34 | 0.010 |
Why?
|
| Bioterrorism | 1 | 2003 | 13 | 0.010 |
Why?
|
| Rifampin | 1 | 2004 | 191 | 0.010 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 82 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2003 | 120 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 2927 | 0.010 |
Why?
|
| Hepatitis | 1 | 2003 | 93 | 0.010 |
Why?
|
| HIV | 1 | 2003 | 229 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 445 | 0.010 |
Why?
|
| Mutation | 1 | 2002 | 15179 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 1054 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2001 | 157 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 2049 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2004 | 1313 | 0.010 |
Why?
|
| Sepsis | 1 | 2006 | 652 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 4549 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2007 | 1335 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2013 | 3518 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2003 | 1546 | 0.010 |
Why?
|
| Propionibacterium acnes | 1 | 1977 | 25 | 0.010 |
Why?
|
| Listeriosis | 1 | 1977 | 35 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2003 | 962 | 0.010 |
Why?
|
| Macrophages | 1 | 1977 | 1304 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2003 | 2341 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1977 | 104 | 0.000 |
Why?
|
| Listeria monocytogenes | 1 | 1977 | 52 | 0.000 |
Why?
|
| Immunity, Cellular | 1 | 1977 | 419 | 0.000 |
Why?
|
| Spleen | 1 | 1977 | 676 | 0.000 |
Why?
|
| Skin | 1 | 1977 | 1259 | 0.000 |
Why?
|
| Liver | 1 | 1977 | 2961 | 0.000 |
Why?
|